Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

作者：Kim Alexander Papp, Richard G B Langley, Mark Lebwohl, Gerald G. Krueger, Philippe O. Szapary, Newman M. Yeilding, Cynthia A. Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich · 发表于：The Lancet · 年份：2008 · DOI：10.1016/s0140-6736(08)60726-6 · 被引用次数：1365 · 研究领域：Psoriasis: Treatment and Pathogenesis、Dermatology and Skin Diseases、Asthma and respiratory diseases